Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
ELIGIBILITY~Pre-registration inclusion:~Must be at least 18 years of age and capable of giving informed consent.~High risk breast cancer defined as the following:~* stage IV breast cancer~* inflammatory breast carcinoma~* Stage II breast cancer with more than 10 positive axillary lymph nodes~* Stage IIIA breast cancer (tumor greater than or equal to 5 cm with at least one positive axillary lymph note)~A minimum of 3 grams of non-necrotic, resectable breast cancer.~ECOG Performance Score (PS) less than (\<3.0).~Pre-registration exclusion:~* ECOG Performance Score (PS) greater than or equal to 3.0.~* Congenital or acquired immunodeficiency including infection with human immunodeficiency virus.~* Significant behavioral or psychological problems that preclude adequate informed consent or follow-up.~Registration inclusion:~* Major clinical responses defined as either Complete response (CR) by conventional staging work-up such as CT scan and bone scan.~Or Stable partial response (PR) defined as more than 50% tumor reduction which remains stable by serial CT scans or bone scans over a 3-month span.~* More than 60 micrograms of HSP70 purified.~* ECOG Performance Score(PS) less than 3.0.~* Greater than or equal to 4 weeks post cytotoxic therapy.~Registration exclusion:~* ECOG Performance Score(PS) greater than or equal to 3.0.~* Purification of HSP70 is unsuccessful qualitatively or quantitatively.~* On other investigational therapy for breast cancer.~* Positive serum or urine pregnancy test.~* Impaired renal function (serum creatinine \> 2.0) and hepatic function (bilirubin more than 2.0 x and transaminase more than 4.0 x of the upper normal limit).~* Significant active infection requiring hospitalization;~* Acquired immunodeficiency or active autoimmune diseases.~* Significant behavioral or psychological problems that prevent adequate follow-up.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).